You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Low-dose IL2-based Immunomodulatory therapy for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): It has been recently shown that CD4+ and CD8+ T lymphocytes are critically involved in the collateral brain injury and neurological deficit associated with experimental stroke. Naturally occurring CD4+CD25+Foxp3+ (nTreg) cells derived from thymus play a key role in modulating the function of effector T cells and antigen- presenting cells that maintain self tole ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of TAK1 Compounds for Neonatal Onset Multisystem Inflammatory Disease

    SBC: CONFLUENCE LIFE SCIENCES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Cryopyrin-associated periodic syndromes (CAPS) are a family of rare autoinflammatory diseases of which neonatal-onset multisystem inflammatory disease (NOMID) is the most severe phenotype. NOMID is characterized by NLRP3 activating mutations resulting in excessive interleukin- 1?IL-1?and IL-18 production associated with recurrent fever, rash, skeletal lesions, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A new two-drug combination therapy for noise-induced hearing loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): Noise is the most common occupational and environmental hazard, thus it is not surprising that noise-induced hearing loss (NIHL) is the second most common form of sensorineural hearing deficit, second only to age-related hearing loss (presbycusis). Although therapeutics that target the free radical pathway have shown promise for reducing NIHL, there are no FDA- ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Manufacturing of Growth Factors to Enable Cardiopoietic Stem Cell Therapy for Hea

    SBC: APT THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cardiopoietic cell therapy significantly improved left ventricular function, blunted pathological remodeling, and functional outcomes in animal models and Phase I/II clinical trial of heart failure patients. There is ongoing Phase III trial. In this therapeutic approach, bone marrow-derived mesenchymal stem cells are engaged into cardiac stem cells by exposing ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Software for Early Detection of Diabetic Neuropathy

    SBC: LICKENBROCK TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The main objective of this SBIR Phase I research is to develop and test a software prototype. The prototype will lead to a software product. It will be a clinical tool that helps clinicians to assess the condition of pa tients who are at risk of or who have diabetic neuropathy. The software will analyze optically sectioned images of subbasal nerve fiber layers ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Inhaled Therapy for Idiopathic Pulmonary Fibrosis

    SBC: ANTEGRIN THERAPEUTICS, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease that affects an estimated 133,000 patients in the U.S. and more than 5 million worldwide. Median survival time after diagnosis is only 2-3 years, with a 5-year mortality rate exceeding 50%. IPF is the leading indication for lung transplant in most large treatment centers. The hallmark of the disease i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid Magnetomotive Thrombolysis for Stroke

    SBC: Pulse Therapeutics, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Acute ischemic stroke (AIS) is the result of a blood clot in a cerebral artery. It remains a leading killer and the leading cause of long-term disabilit, annually impacting over 700,000 Americans [10]. Because brain tissue rapidly dies, time to reperfusion is critical in both preventing death and improving neurological outcomes. While current annual costs relat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Human Apyrase to Disrupt Cancer Therapy

    SBC: APT THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an optimized human apyrase, APT102. With the Phase I grant support, we will determine whether APT102, al ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Therapeutic Agents for Diabetic Ulcers

    SBC: AUXAGEN, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetes mellitus afflicts 20.8 million people, or 7% of the population, in the United States. Fifteen percent, or 2.4 million people, will develop diabetic foot ulcers in their life time. Diabetic foot ulceration and i nfections are a major cause of hospitalization of diabetic patients. The direct and indirect costs of ulcer management and treatment exceed 10 ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a standardized kit and normal reference profile for circular RNAs in the nervous system

    SBC: COFACTOR GENOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Modified ribonucleic acids (RNA) are important regulators of translation and other cellular pathways. Non- coding RNAs like microRNAs play significant roles in neuronal development, and can serve as biomarkers for psychiatric disorders. Another such modified RNA is circular RNA (circRNA), a non-coding transcript present in the cytoplasm. Since circRNAs are pres ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government